TOFACITINIB 5mg. IP

Belongs to a class of drugs called Janus kinase inhibitors that decreases inflammation in the body. A valuable therapy for moderate to severe rheumatoid arthritis in adult patients who are intolerant or have inadequate response to disease-modifying antirheumatic drugs. (Dhillon, 2017) A convenient and well-tolerated therapeutic option for patients with moderate-to-severe plaque psoriasis. (Hervé Bachelez 1, 2015) Demonstrates improvement in health-related quality of life and patient-reported symptoms in patients with moderate to severe plaque psoriasis. (Steven R Feldman, 2016) An effective therapeutic option for rheumatoid arthritis and a promising therapy for psoriasis. (A K Gupta, 2017) Represents as a new therapeutic option for ulcerative colitis. (Julián Panés, 2019) Reduces rheumatoid arthritis signs and symptoms as well as improves physical function. (Paul Bird, 2019) A beneficial therapeutic choice in patients with inadequate response to biologic DMARDs or with methotrexate intolerance. (Naoki Iwamoto, 2017)